SAR 252067

Drug Profile

SAR 252067

Alternative Names: Anti-LIGHT; Anti-LIGHT antibody; Anti-LIGHT monoclonal antibody; MDGN-002; Research programme: anti-LIGHT monoclonal antibody - sanofi-aventis; SAR252067

Latest Information Update: 30 Dec 2016

Price : $50

At a glance

  • Originator Kyowa Hakko Kirin; La Jolla Institute for Allergy & Immunology
  • Developer Kyowa Hakko Kirin; Sanofi
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Crohn's disease; Ulcerative colitis

Most Recent Events

  • 15 Dec 2016 Medgenics is now called Aevi Genomic Medicine
  • 06 Jun 2016 Kyowa Hakko Kirin and Medgenics enter into a licensing agreement for the development and commercialisation of SAR 252067
  • 06 Jun 2016 Medgenics plans a signal finding trial Inflammatory bowel disease (In Children)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top